Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

VAXART INC. — Lobbying — Receipts Report

LD-2 disclosure · 4th Quarter - Termination

VAXART INC.

via RICCHETTI INCORPORATED

4th Quarter (Oct 1 - Dec 31) · 2022Posted Jan 18, 2023Filing document ↗LDA record ↗

Income$80Kfee reported

Client

Name: VAXART INC.
Description: Vaccine development
Location: California · United States of America

Registrant

Firm: RICCHETTI INCORPORATED
Description: Lobbying and consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medical/Disease Research/Clinical Labs
Legislative and regulatory policies regarding oral vaccine development and funding
LobbyistsJEFF RICCHETTI
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.